Trending

Nektar Therapeutics

Nektar lifted by Merck alliance for bempeg, new trial funding

Nektar lifted by Merck alliance for bempeg, new trial funding

Nektar Therapeutics is waiting on multiple data readouts for its lead drug bempegaldesleukin paired with strategic partner Bristol-Myers

X

Nektar lifted by Merck alliance for bempeg, new trial funding

https://pharmaphorum.com/news/nektar-lifted-by-merck-alliance-for-bempeg-new-trial-funding/

Nektar pulls pain drug after bruising FDA panel meeting

Nektar pulls pain drug after bruising FDA panel meeting

Nektar Therapeutics has opted to withdraw its marketing application for new opioid painkiller oxycodegol after an FDA advisory

X

Nektar pulls pain drug after bruising FDA panel meeting

https://pharmaphorum.com/news/nektar-pulls-pain-drug-after-bruising-fda-panel-meeting/

Nektar, BioMarin, and Alnylam top list of biotech M&A targets

Nektar, BioMarin, and Alnylam top list of biotech M&A targets

With Takeda’s £46 billion acquisition of Shire, it’s been a busy year for pharma M&A – and according

X

Nektar, BioMarin, and Alnylam top list of biotech M&A targets

https://pharmaphorum.com/news/nektar-biomarin-and-alnylam-top-list-of-biotech-ma-targets/

BMS makes record $1.8bn bet on Nektar cancer drug

BMS makes record $1.8bn bet on Nektar cancer drug

Bristol-Myers Squibb scored a first-in-class approval with cancer immunotherapy Opdivo just a few years ago – could it

X

BMS makes record $1.8bn bet on Nektar cancer drug

https://pharmaphorum.com/news/bms-makes-record-1-8bn-bet-on-nektar-cancer-drug/

BMS and Nektar to pair Opdivo with natural killer cell drug

BMS and Nektar to pair Opdivo with natural killer cell drug

BMS and Nektar’s combination latest in frenzied immunotherapy field

X

BMS and Nektar to pair Opdivo with natural killer cell drug

https://pharmaphorum.com/news/bms-nektar-pair-opdivo-natural-killer-cell-drug/

CONTINUE TO SITE >

Close in 10 seconds

Pharmaphorum.com